Ignite Creation Date:
2024-05-06 @ 3:57 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04813497
Status:
COMPLETED
Last Update Posted:
2022-06-01
First Post:
2021-03-21
Brief Title:
Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members
Sponsor:
Grand Hôpital de Charleroi
Organization:
Grand Hôpital de Charleroi
Study Overview
Official Title:
Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members Protocol for an Interventional Cohort Study in 2020-2021
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Grand Hôpital de Charleroi GHdC had to organize the vaccination of its staff in December 2021 against SARS-CoV-2On the sidelines of this vaccination campaign the management committee agreed to document the knowledge of the SARS-CoV-2 serology of all the staff of the establishment before this vaccination campaign as well as a few weeks after vaccination
In November 2021 the Belgian government decided to offer a third dose of vaccine against SARS-CoV-2 virus The GHdC managment committee has agreed to continue monitoring SARS-CoV-2 serology for members who receive their third dose of vaccine
In November 2021 the Belgian government decided to offer a third dose of vaccine against SARS-CoV-2 virus The GHdC managment committee has agreed to continue monitoring SARS-CoV-2 serology for members who receive their third dose of vaccine
Detailed Description:
Grand Hôpital de Charleroi GHdC staff were exposed to the risk of SARS-CoV-2 infection during the first half of 2020 a seroprevalence survey conducted in the summer of 2020 after the first wave of the epidemic and before the second wave thus revealed a significant seroprevalence because of its exposure This study because of its high participation rate also showed the sustained interest of the agents in knowing their serology either for personal reasons or for the purposes of recognition as an occupational disease
The GHdC decided in December 2020 to organize as soon as possible the vaccination of its salaried and self-employed employees who wish to take advantage of this opportunity On the sidelines of this vaccination campaign the management committee agreed to document the knowledge of the SARS-Cov-2 serology of all the staff of the establishment before this vaccination campaign as well as a few weeks after vaccination This knowledge must better organize the disease prevention strategy both with regard to the staff themselves and the patients for whom they are called upon to treat
When the Belgian government decided in November 2021 to offer a third dose of vaccine and start it up in hospitals the GHdC managment committee has agreed to continue monitoring SARS-CoV-2 serology for members who agree to receive their third dose of vaccine
The GHdC decided in December 2020 to organize as soon as possible the vaccination of its salaried and self-employed employees who wish to take advantage of this opportunity On the sidelines of this vaccination campaign the management committee agreed to document the knowledge of the SARS-Cov-2 serology of all the staff of the establishment before this vaccination campaign as well as a few weeks after vaccination This knowledge must better organize the disease prevention strategy both with regard to the staff themselves and the patients for whom they are called upon to treat
When the Belgian government decided in November 2021 to offer a third dose of vaccine and start it up in hospitals the GHdC managment committee has agreed to continue monitoring SARS-CoV-2 serology for members who agree to receive their third dose of vaccine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None